POLYMER-ENCAPSULATED GENETICALLY-MODIFIED CELLS CONTINUE TO SECRETE HUMAN NERVE GROWTH-FACTOR FOR OVER ONE-YEAR IN RAT VENTRICLES - BEHAVIORAL AND ANATOMICAL CONSEQUENCES
Sr. Winn et al., POLYMER-ENCAPSULATED GENETICALLY-MODIFIED CELLS CONTINUE TO SECRETE HUMAN NERVE GROWTH-FACTOR FOR OVER ONE-YEAR IN RAT VENTRICLES - BEHAVIORAL AND ANATOMICAL CONSEQUENCES, Experimental neurology, 140(2), 1996, pp. 126-138
The long-term delivery of growth factors and other proteins into the C
NS at putatively therapeutic yet safe levels continues to be technical
ly constrained. fn the present studies, the gene encoding human nerve
growth factor (hNGF), introduced into a dihydrofolate reductase-based
pNUT expression vector system, was engineered into a clonal. baby hams
ter kidney (BHK) cell line. BHK-hNGF23 and mock-transfected cells were
encapsulated in an immunoisolating polymeric device and transplanted
into the lateral ventricles of healthy young adult rats for 13.5 month
s. As measured by ELISA, nanogram quantities of hNGF were released by
encapsulated cells both prior to implantation (3.6 +/- 0.8 ng/device/2
4 h) and upon removal from rat lateral ventricles after 13.5 months in
vivo (2.2 +/- 0.4 ng/device/24 h). In addition, the hNGF released int
o the tissue culture medium was biologically active. Longterm encapsul
ated cell survival was confirmed by histologic analysis. The presence
of genomic DNAs (hNGF transgene), as determined by PCR analyses, revea
led that the transgene copy number from the recovered BHK-hNGF23 cells
after 13.5 months in vivo was equivalent to preimplant levels. No del
eterious effects from hNGF were detectable on body weight, mortality r
ate, motor/ambulatory function, or cognitive function as assessed with
the Morris water maze and delayed matching to position in healthy you
ng adult rats. in addition, there was no evidence that hNGF from these
encapsulated cells produced hyperalgesia. Only tests of somatosensory
thresholds revealed statistically significant effects related to the
hNGF delivered in the present study, and that effect was Limited to a
decrease in the number of trials to asymptote. Animals receiving BHK-h
NGF23 implants exhibited a marked hypertrophy of cholinergic neurons w
ithin the striatum (22% increase) and nucleus basalis (7% increase) bu
t not the medial septum ipsilateral to the capsule. Moreover a robust
sprouting of cholinergic fibers was observed within the frontal cortex
and lateral septum proximal to the implant. These results indicate th
at encapsulated xenogeneic cells provide a safe and effective method f
or the long-term delivery of hNGF and potentially other neurotrophic f
actors within the CNS. (C) 1996 Academic Press, Inc.